The promising results of preclinical studies have led to an initiation of a large number of clinical trials investigating the therapeutic efficacy of recombinant human TRAIL (rhTRAIL) or monoclonal antibodies (mAbs) against TRAIL receptors (TRAILRs) in cancer patients as monotherapy or in combination with chemotherapy [5,6,7]. The gene discussed is TNFSF10; the disease is cancer.